{'fraction_non_alphanumeric': 0.017447199265381085, 'fraction_numerical': 0.0, 'mean_word_length': 4.989010989010989, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A perspective on teaching medical ethics. Report of the Committee on Ethics of the American Heart Association.

SEVERE PSORIASIS can be a painful condition characterized by scaling of the skin, itching, bleeding, and disfigurement. Patients have been known to commit suicide rather than face its torments. There is as yet no fully satisfactory explanation of the cause of psoriasis, nor is there an adequate treatment for its more severe forms. Recently, a new drug was developed and approved for clinical testing in order to establish safety and efficacy. The drug was intended for application only in the most severe cases of psoriasis not responding to other forms of treatment. Midway in the testing program, an unusually high frequency of cerebral vascular disease sometimes involving paralysis, loss of speech, and even death was observed in patients taking the drug. Testing was stopped before any real estimate of efficacy was available. It was estimated that as many as twenty-five percent of psoriatic patients treated with the drug might develop cerebral vascular complications.